SINOPHARM GROUP 1/5/O.N. (X2S1) — Net Asset Quality Index
SINOPHARM GROUP 1/5/O.N. (X2S1) has a Net Asset Quality Index of 34.4% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €390.36 Billion minus total liabilities of €256.20 Billion yields net assets of €134.16 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read SINOPHARM GROUP 1/5/O.N. (X2S1) total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
SINOPHARM GROUP 1/5/O.N. Net Asset Quality Index Over Time (2021–2025)
This chart shows how SINOPHARM GROUP 1/5/O.N.'s Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 34.4%, representing net assets of €134.16 Billion against total assets of €390.36 Billion EUR. For live market cap and overall valuation, see X2S1 market cap overview.
Annual Net Asset Quality Index for SINOPHARM GROUP 1/5/O.N. (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for SINOPHARM GROUP 1/5/O.N. from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See SINOPHARM GROUP 1/5/O.N. (X2S1) shareholders funds for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 34.4% | €134.16 Billion | €390.36 Billion | €256.20 Billion | ▲ +2.1 pp |
| 2024 | 32.2% | €126.69 Billion | €392.83 Billion | €266.14 Billion | ▲ +0.9 pp |
| 2023 | 31.4% | €120.32 Billion | €383.39 Billion | €263.08 Billion | ▲ +1.2 pp |
| 2022 | 30.2% | €110.07 Billion | €364.78 Billion | €254.71 Billion | ▲ +0.5 pp |
| 2021 | 29.7% | €99.65 Billion | €335.41 Billion | €235.76 Billion | — |